末梢性耳性めまい症例に対するATPの薬量効果の検討--二重盲検試験による用量別薬効の検定

概要

論文の詳細を見る
The antivertiginous dose effects of ATP were evaluated, in a double blind control study comparing between the dose of 300mg and of 150mg daily for four weeks in 168 patients with the peripheral vestibular disorders.1. Materials: 69 cases with Meniere's disease, 18 cases with benign paroxismal positional vertigo, 5 cases with vestibular neuronitis, and 62 cases with the other similar and marginal diseases to Meniere's disease were selected.2. Methods: The clinical subjective signs and symptoms in these cases were evaluated every two-weeks both by the doctors and patients themselves. The objective symptoms in the equilibrium and auditory examinations were also evaluated at the first examination before prescribing treatment, the second after two weeks, and the last after four weeks, by the same doctors. Each medication was designed in matched pair group method for the double control trial. Each patient was examined by the same doctors to eliminate variation in interpretation of the status of the patients conditions prior to the control study, and was also evaluated by the same doctors and the Committee of the Data Fixation, restpectively.3. Results: The statistical comparison between the antivertiginous drug effects of 300mg and of 150mg ATP daily for four weeks showed that the 300mg dosage was significantly more preference than the 150 dosage in the subjective and objective grobal evaluations in the patients with peripheral vestibular disorders. However, no significant preference between the two dosages was revealed in the subjective symptoms except in headache. The confrontation between the two dosages, on the other hand, showed more significant difference in spontaneous nystagmus, positional nystagmus and caloric nystagmus examinations. Side-effects were minimal, and only four patients reported tinnitus, sleepy, stomatitis and constipation.
耳鼻咽喉科臨床学会の論文

末梢性耳性めまい症例に対するATPの薬量効果の検討--二重盲検試験による用量別薬効の検定

スポンサーリンク

概要

著者

関連論文

スポンサーリンク